Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
88 studies found for:    "Inflammatory breast cancer"
Show Display Options
Rank Status Study
1 Recruiting Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer
Interventions: Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: Docetaxel;   Biological: Trastuzumab
2 Completed Establishing an Inflammatory Breast Cancer Registry
Condition: Inflammatory Breast Cancer
Intervention:
3 Completed Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia
Condition: Inflammatory Breast Cancer
Intervention:
4 Recruiting Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane
5 Recruiting Case-Control Study of Inflammatory Breast Cancer in North Africa
Condition: Inflammatory Breast Cancer
Intervention:
6 Not yet recruiting Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Condition: Inflammatory Breast Carcinoma
Interventions: Drug: 89Zr-bevacizumab;   Procedure: FDG-PET/CT;   Procedure: MRI scan;   Procedure: Tumor biopsies
7 Completed Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
8 Active, not recruiting Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel;   Drug: Paclitaxel
9 Completed Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Conditions: Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
10 Unknown  Dose-escalation Study of Oral CX-4945
Conditions: Advanced Solid Tumors;   Breast Cancer;   Inflammatory Breast Cancer;   Castleman's Disease;   Multiple Myeloma
Intervention: Drug: CX-4945 oral formulation
11 Recruiting Olaparib and Radiotherapy in Inoperable Breast Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Inflammatory Breast Carcinoma;   Triple-Negative Invasive Breast Carcinoma
Interventions: Radiation: radiotherapy;   Drug: olaparib
12 Active, not recruiting Inflammatory Breast Cancer (IBC) Registry
Condition: Breast Cancer
Interventions: Other: Interview;   Procedure: Blood and Tissue Collection
13 Completed Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis
Condition: Breast Neoplasms
Intervention:
14 Terminated
Has Results
Phase II Neoadjuvant in Inflammatory Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Paclitaxel;   Drug: 5-Fluorouracil (5-FU);   Drug: Epirubicin;   Drug: Cyclophosphamide
15 Active, not recruiting TKI258 for Metastatic Inflammatory Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: Dovitinib
16 Active, not recruiting Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: epirubicin hydrochloride;   Drug: fluorouracil
17 Completed Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Biological: Bevacizumab
18 Terminated
Has Results
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
Condition: Breast Cancer
Interventions: Biological: herceptin;   Drug: carboplatin;   Drug: docetaxel;   Procedure: conventional surgery;   Procedure: radiation therapy
19 Recruiting Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Panitumumab;   Drug: Nab-paclitaxel;   Drug: Carboplatin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
20 Completed
Has Results
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Gemcitabine;   Drug: Epirubicin;   Drug: Albumin-bound Paclitaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years